公司资料
Edwards Lifesciences 股价、新闻与催化剂
- 股票代码:
- EW
- 交易所:
- NYSE
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
88.25 USD (-1.15%)
收盘价
最后更新: 2026年9月17日
50.5B USD
市值
股价为何变动
截至 2026年9月17日，EW 下跌 1.15%，收于 $88.25。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Edwards Lifesciences is a medical technology company best known for transcatheter heart valve therapies and critical care monitoring. The business is centered on structural heart innovation and procedure adoption.
所在地与行业分类
Headquartered in the United States and listed on NYSE, Edwards is a global medtech company with strong exposure to cardiovascular procedures. It sits outside biotech and closer to high-end medical devices.
商业模式特征
The company generates revenue through transcatheter valve systems, monitoring technologies, and related procedure-based products. Investors focus on procedure growth, product expansion, and how well the company can keep widening adoption in structural heart care.
生物医药行业定位
Edwards is not biotech proper, but it occupies a premium position in healthcare innovation. It tends to move on device adoption and clinical uptake rather than on drug approvals or pipeline readouts.
未来催化剂
- Edwards Lifesciences is likely to be driven by TAVR demand, EVOQUE adoption in tricuspid therapy, and continued SAPIEN franchise strength. The key question is whether the update shows enough repeatable demand to look like a durable revenue driver rather than a one-quarter bump. If adoption broadens, sentiment can improve faster than the reported numbers alone would suggest.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。